KUMC Department of Cancer Biology
@KUMCCancerBio
Official account of the Cancer Biology Department at the University of Kansas Medical Center
63 Following 67 Followers 138 Posts
Latest posts 5
September Spotlight: Scott Chin, Graduate Student
Scott Chin is a 2nd year graduate student at the University of Kansas Medical Center MD/PhD program in Dr. David Akhavan’s laboratory in the Department of Cancer Biology.
Scott completed his undergraduate at the University of California, Los Angeles with a degree in Microbiology, Immunology, and Molecular Genetics in 2021. As an undergraduate, he developed his basic immunology foundation under the mentorship of Dr. Maureen Su to investigate the epigenetic mechanisms of Natural Killer cell and T cell function at homeostasis and viral infection. Following graduation, he joined Dr. Anusha Kalbasi’s lab as a research associate to study a novel therapy combining radiation and immunotherapy to reprogram the tumor microenvironment in preclinical models and translated this to the clinic for patients with undifferentiated pleomorphic sarcoma in a Phase I clinical trial.
Scott joined the KUMC MD/PhD program in 2023 and is mentored by Dr. David Akhavan, focusing on tuning and enhancing CAR T cell function and survival in the hostile tumor microenvironment through cellular engineering and pharmacological approaches. His research interest centers on the complex signals that dictate an effective, sustained response by the immune system to cancer. Through this, he hopes to develop novel approaches to address challenges in solid tumors from a patient perspective and bring these therapies to the clinic.
Outside of the lab, Scott enjoys listening to videography, traveling, and listening to live music.
Scott Chin is a 2nd year graduate student at the University of Kansas Medical Center MD/PhD program in Dr. David Akhavan’s laboratory in the Department of Cancer Biology.
Scott completed his undergraduate at the University of California, Los Angeles with a degree in Microbiology, Immunology, and Molecular Genetics in 2021. As an undergraduate, he developed his basic immunology foundation under the mentorship of Dr. Maureen Su to investigate the epigenetic mechanisms of Natural Killer cell and T cell function at homeostasis and viral infection. Following graduation, he joined Dr. Anusha Kalbasi’s lab as a research associate to study a novel therapy combining radiation and immunotherapy to reprogram the tumor microenvironment in preclinical models and translated this to the clinic for patients with undifferentiated pleomorphic sarcoma in a Phase I clinical trial.
Scott joined the KUMC MD/PhD program in 2023 and is mentored by Dr. David Akhavan, focusing on tuning and enhancing CAR T cell function and survival in the hostile tumor microenvironment through cellular engineering and pharmacological approaches. His research interest centers on the complex signals that dictate an effective, sustained response by the immune system to cancer. Through this, he hopes to develop novel approaches to address challenges in solid tumors from a patient perspective and bring these therapies to the clinic.
Outside of the lab, Scott enjoys listening to videography, traveling, and listening to live music.
Cancer Biology Associate Professor Michael VanSaun, PhD, has been recognized by the Interdisciplinary Graduate Program in Biomedical Sciences (IGBPS) as the AY 2025–2026 Dr. Mark J. Fisher Instructor of the Year!
This award recognizes Dr. VanSaun’s outstanding dedication to teaching, mentorship, and graduate education. We are proud to celebrate this well-deserved achievement!
Congratulations, Dr. VanSaun!
This award recognizes Dr. VanSaun’s outstanding dedication to teaching, mentorship, and graduate education. We are proud to celebrate this well-deserved achievement!
Congratulations, Dr. VanSaun!
Congratulations to Debolina Dasgupta of the Pyaram Lab who successfully defended her PhD dissertation last week with flying colors! 🎓🎉
Throughout her time in the Pyaram Lab, Debolina has consistently demonstrated an unparalleled work ethic, dedication, and commitment to advancing cancer research. She has been an integral part of not only the Pyaram Lab, but the entire Cancer Biology Department.
We are incredibly proud of Debolina and all she has accomplished. Congratulations, Dr. Dasgupta! We are excited to see all that the future holds for you!
Throughout her time in the Pyaram Lab, Debolina has consistently demonstrated an unparalleled work ethic, dedication, and commitment to advancing cancer research. She has been an integral part of not only the Pyaram Lab, but the entire Cancer Biology Department.
We are incredibly proud of Debolina and all she has accomplished. Congratulations, Dr. Dasgupta! We are excited to see all that the future holds for you!
August Spotlight: Thais Sielecki-Dzurdz, PhD-Professor, Cancer Biology and Director, Institute for Advancing Medical Innovation (IAMI)
Thais Sielecki-Dzurdz is a Professor at the University of Kansas Medical Center, with primary appointments in the Department of Cancer Biology, and is the Director of the Institute for Advancing Medical Innovation (IAMI). Her research focuses on moving projects from the lab into full preclinical evaluation.
Dr. Sielecki-Dzurdz developed a deep admiration for chemistry as a highschool student in Maryland. She completed her doctoral training in Chemistry from Colorado State University under the mentorship of Dr. A.I.Meyers, where she developed strong synthetic skills in asymmetric synthesis. She went on to pursue postdoctoral training at Stanford University under the tutelage of Dr. P. Wender. Her research there focused on using photocatalysis to isomerize molecules from the inactive to active forms to allow for activation of drugs in the target tumor cells. Dr. Sielecki-Dzurdz started her pharmaceutical career at DuPont-Merck Pharmaceuticals. She then when on to be V.P. of Research at Cytokine PharmaSciences prior to working with various academic institutions on spinning out promising technologies into start-up companies. She joined KUMC in the spring of 2024.
At KUMC, Dr. Sielecki-Dzurdz leads a highly cross functional and collaborative research program working with multiple projects on optimizing drug candidates and moving those compounds toward IND. Her lab leads the drug discovery effort from high throughput screening to drug candidate selection and multi-gram synthesis. A major goal of her work is to translate these findings into novel therapeutic strategies.
Dr. Sielecki-Dzurdz is passionate about mentoring the next generation of translational scientists with a special focus on mentoring women in science. Outside the lab, she enjoys traveling, fiber arts, and cycling adventures.
Thais Sielecki-Dzurdz is a Professor at the University of Kansas Medical Center, with primary appointments in the Department of Cancer Biology, and is the Director of the Institute for Advancing Medical Innovation (IAMI). Her research focuses on moving projects from the lab into full preclinical evaluation.
Dr. Sielecki-Dzurdz developed a deep admiration for chemistry as a highschool student in Maryland. She completed her doctoral training in Chemistry from Colorado State University under the mentorship of Dr. A.I.Meyers, where she developed strong synthetic skills in asymmetric synthesis. She went on to pursue postdoctoral training at Stanford University under the tutelage of Dr. P. Wender. Her research there focused on using photocatalysis to isomerize molecules from the inactive to active forms to allow for activation of drugs in the target tumor cells. Dr. Sielecki-Dzurdz started her pharmaceutical career at DuPont-Merck Pharmaceuticals. She then when on to be V.P. of Research at Cytokine PharmaSciences prior to working with various academic institutions on spinning out promising technologies into start-up companies. She joined KUMC in the spring of 2024.
At KUMC, Dr. Sielecki-Dzurdz leads a highly cross functional and collaborative research program working with multiple projects on optimizing drug candidates and moving those compounds toward IND. Her lab leads the drug discovery effort from high throughput screening to drug candidate selection and multi-gram synthesis. A major goal of her work is to translate these findings into novel therapeutic strategies.
Dr. Sielecki-Dzurdz is passionate about mentoring the next generation of translational scientists with a special focus on mentoring women in science. Outside the lab, she enjoys traveling, fiber arts, and cycling adventures.